Since LDL cholesterol levels do not necessarily suggest the need to increase statin doses, follow-up measurement of lipid levels is not recommended. published online 19 February 2014 KEYWORDS: cholesterol; chronic kidney disease; dyslipidemia; evidence- based recommendation; systematic review; triglyceride Kidney Disease: Improving Global Outcomes (KDIGO) developed the clinical practice guidelines on lipid manage- ment in 2013 to inform the management of dyslipidemia and the use of cholesterol-lowering medications in all adults and children with known CKD. All forms of CKD were included (non-dialysis-dependent, dialysis-dependent, and kidney transplant recipients). The KDIGO Lipid Guideline Devel- opment Work Group defined the scope of the guideline, gathered evidence, determined topics for systematic review, and graded the quality of evidence that had been summarized by an evidence review team. Searches of the English-language literature were conducted through August 2011 and supple- mented by targeted searches through June 2013. The final modification of the guidelines was informed by the KDIGO Board of Directors and a public review process involving registered stakeholders. The full guideline including 13 recommendations was released on 7 November 2013 and is available at http: //www.kdigo.org/.1 Here we provide a quick summary of the KDIGO recommendations for lipid-lowering treatment separated into assessment of lipid status and pharmacological choles- terol- and triglyceride (TG)-lowering treatment in children and adults with CKD. GUIDELINE DEVELOPMENT PROCESS, EVIDENCE GRADING, AND STAKEHOLDER AND PUBLIC CONSULTATION The Work Group consisted of a truly international group of kidney specialists, diabetologists, cardiologists, epidemiolo- gists, lipidologists, and a professional evidence review team. 